COMMUNIQUÉS West-GlobeNewswire

Nutraville Announces MemoryFuel Launch as Interest Grows Around Creatine Monohydrate, Brain Energy, and Daily Mental Performance
14/08/2026
Tallmadge, OH, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutraville has announced the launch of MemoryFuel, a caffeine-free brain-health powder formulated for adults interested in supporting memory, focus support, mental [...]
More Cancer Patients Are Opting to Preserve Their Tumors
14/08/2026
New Tumor-Preservation Service Opens in Arizona, Giving Patients the Opportunity to Preserve Unadulterated Tumor Tissue for Potential Personalized Cancer Immunotherapy SCOTTSDALE, Ariz., Aug. 13, 2026 (GLOBE NEWSWIRE [...]
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
14/08/2026
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, [...]
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing [...]
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
13/08/2026
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the [...]
Maze Therapeutics Announces Appointments to Its Board of Directors
13/08/2026
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 ( [...]
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial [...]
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
13/08/2026
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined [...]
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
13/08/2026
Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regeneration Continued favorable safety and tolerability profile, [...]
BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026
13/08/2026
MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on [...]
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
13/08/2026
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic [...]
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
13/08/2026
$26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted [...]
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
13/08/2026
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for [...]
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
13/08/2026
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic [...]
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
13/08/2026
Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors Enrolling patients in [...]
Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
13/08/2026
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second [...]
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
13/08/2026
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the [...]
FocalTherics™ Reports Second Quarter 2026 Financial Results
13/08/2026
39% Revenue Increase and 47% Growth in U.S. Procedures FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- [...]
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on [...]

Pages